Cargando…
Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease
The discovery of antiviral agents against SARS-CoV-2 is an important step toward ending the COVID-19 pandemic and to tackle future outbreaks. In this context, the main protease (M(pro)) represents an ideal target for developing coronavirus antivirals, being conserved among different strains and esse...
Autores principales: | Deodato, Davide, Asad, Nadeem, Dore, Timothy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225965/ https://www.ncbi.nlm.nih.gov/pubmed/35760254 http://dx.doi.org/10.1016/j.bmcl.2022.128867 |
Ejemplares similares
-
Hit Expansion of a Noncovalent SARS-CoV-2 Main
Protease Inhibitor
por: Glaser, Jens, et al.
Publicado: (2022) -
Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors
por: Kovalevsky, Andrey, et al.
Publicado: (2023) -
Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small molecules
por: Gentile, Francesco, et al.
Publicado: (2021) -
Discovery and Mechanism
of SARS-CoV-2 Main
Protease Inhibitors
por: Huff, Sarah, et al.
Publicado: (2021) -
Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)